Skip to main content
Premium Trial:

Request an Annual Quote

Emiliem Will Use Invitrogen's SelectScreen Tech to Study Cancer Compounds

NEW YORK (GenomeWeb News) — Emiliem and Invitrogen will screen Emiliem’s multi-kinase inhibitors under a partnership agreement, the companies said today.
 
The companies said they will use Invitrogen’s SelectScreen for kinase and P450 screening and cellular pathway profiling to study Emiliem’s cancer compounds.  
 
The two-phase agreement calls for Invitrogen to confirm specificity and potency of Emiliem’s compounds, to study the effects of these compounds on biological pathways, and to use metabolizing liver enzymes to determine profiles of lead molecules.
 
The SelectScreen service uses enzyme collections and cell lines.
 
Financial terms of the agreement were not disclosed.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.